Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nimesulide + cyclobenzaprine is a combination drug consisting of two active pharmaceutical ingredients: - **Nimesulide** is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the synthesis of prostaglandins, thereby reducing pain and inflammation. - **Cyclobenzaprine** is a centrally acting skeletal muscle relaxant. Its mechanism involves action at the brainstem to reduce skeletal muscle spasm, likely by inhibiting descending serotonergic pathways and diminishing activity of efferent alpha and gamma motor neurons. Cyclobenzaprine does not act directly on skeletal muscles or neuromuscular junctions. This combination would be used for the symptomatic treatment of acute musculoskeletal pain with associated muscle spasm, leveraging both anti-inflammatory/analgesic effects (from nimesulide) and muscle relaxation (from cyclobenzaprine). Both drugs are intended for short-term use due to safety concerns with long-term administration[4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nimesulide + cyclobenzaprine.